Thrombolytic therapy can eliminate thrombotic masses from the deep veins, but its effectiveness is not always predictable. We hypothesize that blood flow may influence the composition of an acute venous thrombus contributing to unpredictable outcomes. The aim of the study was to take advantage of two available well-established models to compare venous thrombus composition under flow and stasis conditions in vivo.
Methods
C57BL/6 mice, 10-12 weeks old, weighing 20-25g, were used in electrolytic (EIM) and ligation (LM) models of VT. Four groups (n = 5) were used to compare the structure of acute (Day (2) and subacute (Day (6) thrombus in the EIM and LM. Venous thrombus was harvested for thrombus weight (TW) measurement and histology. Expression of PAI-1, t-PA, u-PA, and alfa-2-antiplasmin in the vein wall and D-dimer levels in plasma were investigated at Day 2 and 6.
Results
Acute venous thrombus within the EIM was significantly smaller compared to LM (6.2 ± 3.6 vs 26.2 ± 3.6, P < .05). Thrombus formed within the EIM had a significantly higher amount of plasminogen, especially on the surface and in the tail of the thrombus. In addition, a significantly higher concentration of circulating D-Dimer was found within the EIM.
Conclusions
Regional venous blood flow pattern may significantly affect the structure and composition of the venous thrombotic masses. Non-occlusive thrombus has a higher potential to be targeted by the fibrinolytic system and fibrinolytic therapy due to a higher plasminogen content and accessibility for plasminogen activators.
OrtelTLNeumannIAgenoW, et al.American society of hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv2020; 4: 4693–4738.
2.
McCormackTHarrisinghMCHornerDGuideline Committee, et al.. Venous thromboembolism in adults: summary of updated NICE guidance on diagnosis, management, and thrombophilia testing. BMJ2020; 369: m1565.
3.
KakkosSKGohelMBaekgaardN, et al.Editor's Choice - European society for vascular surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg2021; 61: 9–82.
4.
StevensSMWollerSCKreuzigerLB, et al.Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report. Chest2021; 160(6): e545–e608.
5.
Van der HulleTKooimanJden ExterPL, et al.Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemostasis2014; 12: 320–328.
6.
Ruíz-GiménezNSuárezCGonzálezR, et al.Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE registry. Thromb Haemost2008; 100: 26–31.
7.
Di NisioMRaskobGBüllerHR, et al.Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thromb Haemost2017; 117: 784–793.
8.
BrownJDGoodinAJLipGYH, et al.Risk stratification for bleeding complications in patients with venous thromboembolism: application of the HAS-BLED bleeding score during the first 6 months of anticoagulant treatment. J Am Heart Assoc2018; 7(6): e007901.
9.
KahnSRComerotaAJCushmanMAmerican Heart Association Council on Peripheral Vascular Disease Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing, et al.. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American heart association. Circulation2014; 130: 1636–1661.
10.
KhanFRahmanACarrierMMARVELOUS Collaborators, et al.. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ2019; 366: l4363.
11.
ComerotaAJShaydakovME. Surgical management, lytic therapy and venous stenting. In: WilsonSJimenezJVeithF (eds). Vascular Surgery: Principles and Practice. 4th ed. : CRC Press, 2016, pp. 717–738.
12.
ComerotaAJShaydakovME. Thrombolysis and mechanical thrombectomy for deep venous thrombosis and pulmonary embolism. In: MooreWLawrencePOderichG (eds). Vascular and Endovascular Surgery: a Comprehensive review. 9th ed: Elsevier, 2018, pp. 757–770.
13.
DiazJAHawleyAEAlvaradoCM, et al.Thrombogenesis with continuous blood flow in the inferior vena cava. A novel mouse model. Thromb Haemost2010; 104(2): 366–375.
14.
DiazJAWrobleskiSKHawleyAE, et al.Electrolytic inferior vena cava model (EIM) of venous thrombosis. J Vis Exp2011; 53: e2737.
15.
DiazJAAlvaradoCMWrobleskiSK, et al.The electrolytic inferior vena cava model (EIM) to study thrombogenesis and thrombus resolution with continuous blood flow in the mouse. Thromb Haemost2013; 109(6): 1158–1169.
16.
PalmerORShaydakovMERaineyJP, et al.Update on the electrolytic IVC model for pre-clinical studies of venous thrombosis. Res Pract Thromb Haemost2018; 2(2): 266–273.
17.
WojcikBMWrobleskiSKHawleyAE, et al.Interleukin-6: a potential target for post-thrombotic syndrome. Ann Vasc Surg2011; 25(2): 229–239.
18.
National Research Council (US). Committee for the update of the guide for the care and use of laboratory animals. Guide for the care and use of laboratory animals. 8th ed: National Academies Press (US), 2011. Available from.
19.
WrobleskiSKFarrisDMDiazJA, et al.Mouse complete stasis model of inferior vena cava thrombosis. J Vis Exp2011; 52: 2738.
20.
Percie du SertNAhluwaliaAAlamS, et al.Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol2020; 18(7): e3000411.
21.
KillewichLABedfordGRBeachKW, et al.Spontaneous lysis of deep venous thrombi: rate and outcome. J Vasc Surg1989; 9: 89–97.
22.
HolmströmMLindmarkerPGranqvistS, et al.A 6-month venographic follow-up in 164 patients with acute deep vein thrombosis. Thromb Haemost1997; 78: 803–807.
23.
Van RamshorstBvan BemmelenPSHoeneveldH, et al.Thrombus regression in deep venous thrombosis. Quantification of spontaneous thrombolysis with duplex scanning. Circulation1992; 86: 414–419.
24.
MasudaEMKesslerDMKistnerRL, et al.The natural history of calf vein thrombosis: lysis of thrombi and development of reflux. J Vasc Surg1998; 28: 67–73, ; discussion 73-4.
25.
PiovellaFCrippaLBaroneM, et al.Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica2002; 87: 515–522.
26.
PuskasABaloghZHadadiL, et al.Spontaneous recanalization in deep venous thrombosis: a prospective duplex ultrasound study. Int Angiol2007; 26: 53–63.
27.
MacdonaldPSKahnSRMillerN, et al.Short-term natural history of isolated gastrocnemius and soleal vein thrombosis. J Vasc Surg2003; 37: 523–527.
28.
KoitabashiNNiwamaeNTaguchiT, et al.Remarkable regression of massive deep vein thrombosis in response to intensive oral rivaroxaban treatment. Thromb J2015; 13: 13.
29.
KearonC. Natural history of venous thromboembolism. Circulation2003; 107: I22–I30.
30.
SugimotoKHofmannLVRazaviMK, et al.The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions. J Vasc Surg2003; 37: 512–517.
31.
GrunwaldMRHofmannLV. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis. J Vasc Intervent Radiol2004; 15: 347–352.
32.
WatsonLBroderickCArmonMP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev2014; 11(11): CD002783.
33.
MeissnerMHZierlerBKBergelinRO, et al.Markers of plasma coagulation and fibrinolysis after acute deep venous thrombosis. J Vasc Surg2000; 32: 870–880.
34.
AlbeshriHKaminskiBMattinM, et al.D-Dimer Level and Location of the Deep Venous Thrombosis. JVS-VL, 2018, vol 6, p. 293.
35.
AnoopPChappellPKulkarniS, et al.Evaluation of an immunoturbidimetric D-dimer assay and pretest probability score for suspected venous thromboembolism in a district hospital setting. Hematology2009; 14: 305–310.
36.
LegnaniCCiniMScarvelisD, et al.Multicenter evaluation of a new quantitative highly sensitive D-dimer assay, the hemosil D-dimer HS 500, in patients with clinically suspected venous thromboembolism. Thromb Res2010; 125: 398–401.
37.
VedanthamSGoldhaberSZJulianJA, et al.Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med2017; 377: 2240–2252.
38.
ShaydakovMEComerotaAJLurieF. Primary venous insufficiency increases risk of deep vein thrombosis. J Vasc Surg Venous Lymphat Disord2016; 4: 161–166.
39.
DiazJASahaPCooleyB, et al.Choosing a mouse model of venous thrombosis: a consensus assessment of utility and application. J Thromb Haemostasis2019; 17(4): 699–707.
